Published in J Korean Med Sci on September 24, 2009
Treatment outcome of localized prostate cancer by 70 Gy hypofractionated intensity-modulated radiotherapy with a customized rectal balloon. Radiat Oncol J (2014) 0.85
Dosimetric effects of the acuros XB and anisotropic analytical algorithm on volumetric modulated arc therapy planning for prostate cancer using an endorectal balloon. Radiat Oncol (2015) 0.77
The Effectiveness of Intensity Modulated Radiation Therapy versus Three-Dimensional Radiation Therapy in Prostate Cancer: A Meta-Analysis of the Literatures. PLoS One (2016) 0.75
Toxicity of tomotherapy-based simultaneous integrated boost in whole-pelvis radiation for prostate cancer. Yonsei Med J (2015) 0.75
Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC) Int J Radiat Oncol Biol Phys (1995) 15.12
Sample size and optimal designs for reliability studies. Stat Med (1998) 6.80
Fractionation and protraction for radiotherapy of prostate carcinoma. Int J Radiat Oncol Biol Phys (1999) 4.27
Dose escalation with three-dimensional conformal radiation therapy affects the outcome in prostate cancer. Int J Radiat Oncol Biol Phys (1998) 3.82
High-dose intensity modulated radiation therapy for prostate cancer: early toxicity and biochemical outcome in 772 patients. Int J Radiat Oncol Biol Phys (2002) 2.65
Dosimetry and preliminary acute toxicity in the first 100 men treated for prostate cancer on a randomized hypofractionation dose escalation trial. Int J Radiat Oncol Biol Phys (2005) 2.08
What hypofractionated protocols should be tested for prostate cancer? Int J Radiat Oncol Biol Phys (2003) 1.99
A comparison of daily CT localization to a daily ultrasound-based system in prostate cancer. Int J Radiat Oncol Biol Phys (1999) 1.89
Ultra-high dose (86.4 Gy) IMRT for localized prostate cancer: toxicity and biochemical outcomes. Int J Radiat Oncol Biol Phys (2007) 1.54
Dose escalation with 3D conformal treatment: five year outcomes, treatment optimization, and future directions. Int J Radiat Oncol Biol Phys (1998) 1.34
Hypofractionated intensity-modulated radiotherapy (70 gy at 2.5 Gy per fraction) for localized prostate cancer: long-term outcomes. Int J Radiat Oncol Biol Phys (2005) 1.32
Prostate cancer radiotherapy dose response: an update of the fox chase experience. J Urol (2004) 1.26
Hypofractionated conformal radiotherapy in carcinoma of the prostate: five-year outcome analysis. Int J Radiat Oncol Biol Phys (2003) 1.20
Preliminary observations on biochemical relapse-free survival rates after short-course intensity-modulated radiotherapy (70 Gy at 2.5 Gy/fraction) for localized prostate cancer. Int J Radiat Oncol Biol Phys (2002) 1.19
Intensity-modulated radiotherapy as primary treatment for prostate cancer: acute toxicity in 114 patients. Int J Radiat Oncol Biol Phys (2004) 1.16
Electronic portal imaging device detection of radioopaque markers for the evaluation of prostate position during megavoltage irradiation: a clinical study. Int J Radiat Oncol Biol Phys (1997) 1.11
Automated localization of the prostate at the time of treatment using implanted radiopaque markers: technical feasibility. Int J Radiat Oncol Biol Phys (1995) 1.08
Intensity-modulated radiation therapy (IMRT) for prostate cancer with the use of a rectal balloon for prostate immobilization: acute toxicity and dose-volume analysis. Int J Radiat Oncol Biol Phys (2001) 1.07
The influence of a rectal balloon tube as internal immobilization device on variations of volumes and dose-volume histograms during treatment course of conformal radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys (2002) 1.02
The effect of an endorectal balloon and off-line correction on the interfraction systematic and random prostate position variations: a comparative study. Int J Radiat Oncol Biol Phys (2005) 1.01
Reduced late rectal mucosal changes after prostate three-dimensional conformal radiotherapy with endorectal balloon as observed in repeated endoscopy. Int J Radiat Oncol Biol Phys (2006) 0.99
Rectal dose sparing with a balloon catheter and ultrasound localization in conformal radiation therapy for prostate cancer. Radiother Oncol (2003) 0.98
Rectal wall sparing by dosimetric effect of rectal balloon used during intensity-modulated radiation therapy (IMRT) for prostate cancer. Med Dosim (2005) 0.96
The use of rectal balloon during the delivery of intensity modulated radiotherapy (IMRT) for prostate cancer: more than just a prostate gland immobilization device? Cancer J (2002) 0.95
Conventional vs. conformal radiotherapy for prostate cancer: preliminary results of dosimetry and acute toxicity. Int J Radiat Oncol Biol Phys (1996) 0.94
The impact of geometric uncertainty on hypofractionated external beam radiation therapy of prostate cancer. Int J Radiat Oncol Biol Phys (2003) 0.87
On-line correction of beam portals in the treatment of prostate cancer using an endorectal balloon device. Radiother Oncol (2002) 0.86
Target motion variability and on-line positioning accuracy during external-beam radiation therapy of prostate cancer with an endorectal balloon device. Strahlenther Onkol (2006) 0.86
Tolerance of endorectal balloon in 396 patients treated with intensity-modulated radiation therapy (IMRT) for prostate cancer. Am J Clin Oncol (2006) 0.85
Motion and shape change when using an endorectal balloon during prostate radiation therapy. Radiother Oncol (2006) 0.84
Impact on rectal dose from the use of a prostate immobilization and rectal localization device for patients receiving dose escalated 3D conformal radiation therapy. Urol Oncol (2004) 0.81
3-D Conformal radiotherapy of localized prostate cancer within an Austrian-German multicenter trial: a prospective study of patients' acceptance of the rectal balloon during treatment. Wien Klin Wochenschr (2006) 0.80
Patient tolerance of rectal balloons in conformal radiation treatment of prostate cancer. Int J Radiat Oncol Biol Phys (2006) 0.79
The impact of varying volumes in rectal balloons on rectal dose sparing in conformal radiation therapy of prostate cancer. A prospective three-dimensional analysis. Strahlenther Onkol (2005) 0.77
Identification of 67 histone marks and histone lysine crotonylation as a new type of histone modification. Cell (2011) 5.27
Brown remodeling of white adipose tissue by SirT1-dependent deacetylation of Pparγ. Cell (2012) 2.46
Biopsy of thyroid nodules: comparison of three sets of guidelines. AJR Am J Roentgenol (2010) 2.38
Dose-response relationship in local radiotherapy for hepatocellular carcinoma. Int J Radiat Oncol Biol Phys (2002) 2.18
Fibroblast growth factor receptor 1 gene amplification is associated with poor survival and cigarette smoking dosage in patients with resected squamous cell lung cancer. J Clin Oncol (2012) 1.67
Incidence and mortality of hip fracture among the elderly population in South Korea: a population-based study using the national health insurance claims data. BMC Public Health (2010) 1.57
P63 and EGFR as prognostic predictors in stage IIB radiation-treated cervical squamous cell carcinoma. Gynecol Oncol (2003) 1.54
Improving the capture of adverse event data in clinical trials: the role of the International Atomic Energy Agency. Int J Radiat Oncol Biol Phys (2007) 1.54
Observer variability of Breast Imaging Reporting and Data System (BI-RADS) for breast ultrasound. Eur J Radiol (2007) 1.50
Asian consensus workshop report: expert consensus guideline for the management of intermediate and advanced hepatocellular carcinoma in Asia. Oncology (2011) 1.48
Tumor heterogeneity of FIGO stage III carcinoma of the uterine cervix. Int J Radiat Oncol Biol Phys (2009) 1.39
Phosphorylation-dependent 14-3-3 binding to LRRK2 is impaired by common mutations of familial Parkinson's disease. PLoS One (2011) 1.38
Tumor-infiltrating regulatory T cells delineated by upregulation of PD-1 and inhibitory receptors. Cell Immunol (2012) 1.37
Local radiotherapy as a complement to incomplete transcatheter arterial chemoembolization in locally advanced hepatocellular carcinoma. Liver Int (2005) 1.37
Pilot clinical trial of localized concurrent chemoradiation therapy for locally advanced hepatocellular carcinoma with portal vein thrombosis. Cancer (2008) 1.36
Perfusion CT: noninvasive surrogate marker for stratification of pancreatic cancer response to concurrent chemo- and radiation therapy. Radiology (2008) 1.35
MGMT gene promoter methylation as a potent prognostic factor in glioblastoma treated with temozolomide-based chemoradiotherapy: a single-institution study. Int J Radiat Oncol Biol Phys (2012) 1.31
MDM2 and p53 polymorphisms are associated with the development of hepatocellular carcinoma in patients with chronic hepatitis B virus infection. Carcinogenesis (2008) 1.25
Cooperative activation of PI3K by Ras and Rho family small GTPases. Mol Cell (2012) 1.23
Long-term survival outcomes following internal mammary node irradiation in stage II-III breast cancer: results of a large retrospective study with 12-year follow-up. Int J Radiat Oncol Biol Phys (2013) 1.22
[Cost-of-illness study of asthma in Korea: estimated from the Korea National Health insurance claims database]. J Prev Med Public Health (2006) 1.22
Risk factors and dose-effect relationship for mandibular osteoradionecrosis in oral and oropharyngeal cancer patients. Int J Radiat Oncol Biol Phys (2009) 1.20
Serum CEA as a predictor for the response to preoperative chemoradiation in rectal cancer. J Surg Oncol (2006) 1.17
Combination of external beam irradiation and high-dose-rate intraluminal brachytherapy for inoperable carcinoma of the extrahepatic bile ducts. Int J Radiat Oncol Biol Phys (2003) 1.15
Angiocentric T-cell and NK/T-cell lymphomas: radiotherapeutic viewpoints. Int J Radiat Oncol Biol Phys (2004) 1.15
Ambient particulate matter as a risk factor for suicide. Am J Psychiatry (2010) 1.13
Radiotherapy for hepatocellular carcinoma: an overview. Ann Surg Oncol (2008) 1.10
Radiotherapeutic parameters predictive of liver complications induced by liver tumor radiotherapy. Int J Radiat Oncol Biol Phys (2008) 1.09
CA 19-9 as a predictor for response and survival in advanced pancreatic cancer patients treated with chemoradiotherapy. Int J Radiat Oncol Biol Phys (2008) 1.07
Lung cancer patients who are asymptomatic at diagnosis show favorable prognosis: a korean Lung Cancer Registry Study. Lung Cancer (2008) 1.05
Radiosensitivity enhancement by celecoxib, a cyclooxygenase (COX)-2 selective inhibitor, via COX-2-dependent cell cycle regulation on human cancer cells expressing differential COX-2 levels. Cancer Res (2005) 1.05
The role of postoperative external-beam radiotherapy in the management of patients with papillary thyroid cancer invading the trachea. Int J Radiat Oncol Biol Phys (2006) 0.98
Prognostic value of mucinous histology depends on microsatellite instability status in patients with stage III colon cancer treated with adjuvant FOLFOX chemotherapy: a retrospective cohort study. Ann Surg Oncol (2013) 0.98
A multimodal approach including craniospinal irradiation improves the treatment outcome of high-risk intracranial nongerminomatous germ cell tumors. Int J Radiat Oncol Biol Phys (2012) 0.97
Radiotherapy for solitary plasmacytoma of bone and soft tissue: outcomes and prognostic factors. Ann Hematol (2012) 0.97
Radiotherapeutic strategies in the management of hepatocellular carcinoma. Oncology (2011) 0.97
Clinical results of 3-dimensional conformal radiotherapy combined with transarterial chemoembolization for hepatocellular carcinoma in the cirrhotic patients. Hepatol Res (2003) 0.96
Early on-treatment predictions of clinical outcomes using alpha-fetoprotein and des-gamma-carboxy prothrombin responses in patients with advanced hepatocellular carcinoma. J Gastroenterol Hepatol (2012) 0.96
Real-time single-molecule co-immunoprecipitation analyses reveal cancer-specific Ras signalling dynamics. Nat Commun (2013) 0.95
Clinical significance of cyclooxygenase-2 expression in extranodal natural killer (NK)/T-cell lymphoma, nasal type. Int J Radiat Oncol Biol Phys (2006) 0.94
18F-fluorodeoxyglucose uptake on positron emission tomography as a prognostic predictor in locally advanced hepatocellular carcinoma. Cancer (2011) 0.94
Three cases of diffuse large B-cell lymphoma presenting as primary splenic lymphoma. Yonsei Med J (2005) 0.94
Improved oncologic outcomes with image-guided intensity-modulated radiation therapy using helical tomotherapy in locally advanced hepatocellular carcinoma. J Cancer Res Clin Oncol (2014) 0.94
Reirradiation to the pelvis for recurrent rectal cancer. J Surg Oncol (2011) 0.93
Radiation-induced hepatic toxicity after radiotherapy combined with chemotherapy for hepatocellular carcinoma. Hepatol Res (2007) 0.93
Cost-effective mammography screening in Korea: high incidence of breast cancer in young women. Cancer Sci (2009) 0.93
Opportunities and challenges in the era of molecularly targeted agents and radiation therapy. J Natl Cancer Inst (2013) 0.93
Role of radiotherapy for primary orbital lymphoma. Am J Clin Oncol (2002) 0.93
Clinical significance of margin status in postoperative radiotherapy for extremity and truncal soft-tissue sarcoma. Int J Radiat Oncol Biol Phys (2007) 0.92
Expression of estrogen receptor-beta in normal mammary and tumor tissues: is it protective in breast carcinogenesis? Breast Cancer Res Treat (2003) 0.92
Alteration of cancer pain-related signals by radiation: proteomic analysis in an animal model with cancer bone invasion. Int J Radiat Oncol Biol Phys (2005) 0.92
Multidisciplinary management of nonresectable hepatocellular carcinoma. Oncology (2011) 0.92
Nanoscale, electrified liquid jets for high-resolution printing of charge. Nano Lett (2010) 0.92
Tumor volume changes assessed by three-dimensional magnetic resonance volumetry in rectal cancer patients after preoperative chemoradiation: the impact of the volume reduction ratio on the prediction of pathologic complete response. Int J Radiat Oncol Biol Phys (2009) 0.92
Proposal of pharmacogenetics-based warfarin dosing algorithm in Korean patients. J Hum Genet (2011) 0.91
A comparative study of volumetric analysis, histopathologic downstaging, and tumor regression grade in evaluating tumor response in locally advanced rectal cancer following preoperative chemoradiation. Int J Radiat Oncol Biol Phys (2006) 0.91
Dose optimization of fractionated external radiation and high-dose-rate intracavitary brachytherapy for FIGO stage IB uterine cervical carcinoma. Int J Radiat Oncol Biol Phys (2002) 0.91
Early clinical experience and outcome of helical tomotherapy for multiple metastatic lesions. Int J Radiat Oncol Biol Phys (2008) 0.90
Age-specific prostate-specific antigen reference ranges in Korean men. Urology (2007) 0.90
Clinical outcomes for T1-2N0-1 oral tongue cancer patients underwent surgery with and without postoperative radiotherapy. Radiat Oncol (2010) 0.90
Coxsackie and adenovirus receptor binding ablation reduces adenovirus liver tropism and toxicity. Hum Gene Ther (2005) 0.90
The efficacy of hepatic resection after neoadjuvant transarterial chemoembolization (TACE) and radiation therapy in hepatocellular carcinoma greater than 5 cm in size. J Korean Med Sci (2009) 0.90
Is there a clinical benefit to adaptive planning during tomotherapy in patients with head and neck cancer at risk for xerostomia? Am J Clin Oncol (2012) 0.90
The optimal selection of radiotherapy treatment for hepatocellular carcinoma. Gut Liver (2012) 0.90
Gastroduodenal complications after concurrent chemoradiation therapy in patients with hepatocellular carcinoma: endoscopic findings and risk factors. Int J Radiat Oncol Biol Phys (2010) 0.90
Treatment failure in intracranial primary germinomas. Childs Nerv Syst (2007) 0.90
Epigenetic regulation of hypoxia inducible factor in diseases and therapeutics. Arch Pharm Res (2013) 0.89
The combination of vitamin D deficiency and mild to moderate chronic kidney disease is associated with low bone mineral density and deteriorated femoral microarchitecture: results from the KNHANES 2008-2011. J Clin Endocrinol Metab (2014) 0.89
Gemcitabine monotherapy as salvage chemotherapy in heavily pretreated metastatic breast cancer. Breast Cancer Res Treat (2005) 0.89
Phase II trial of S-1 and concurrent radiotherapy in patients with locally advanced pancreatic cancer. Cancer Chemother Pharmacol (2008) 0.89
Is local radiotherapy still valuable for patients with multiple intrahepatic hepatocellular carcinomas? Int J Radiat Oncol Biol Phys (2009) 0.89
Clinical significance of progesterone receptor and HER2 status in estrogen receptor-positive, operable breast cancer with adjuvant tamoxifen. J Cancer Res Clin Oncol (2011) 0.89
Longitudinal standards for height and height velocity in Korean children and adolescents: the Kangwha study. [corrected]. J Korean Med Sci (2013) 0.89
Elevated serum aminotransferase level as a predictor of intracerebral hemorrhage: Korea medical insurance corporation study. Stroke (2005) 0.88
Changes in morbidity and medical care utilization after the recent economic crisis in the Republic of Korea. Bull World Health Organ (2003) 0.88
Combination treatment of localized concurrent chemoradiation therapy and transarterial chemoembolization in locally advanced hepatocellular carcinoma with intrahepatic metastasis. Cancer Chemother Pharmacol (2012) 0.88
Low-dose craniospinal irradiation as a definitive treatment for intracranial germinoma. Radiother Oncol (2008) 0.88
Barrier protective effects of rosmarinic acid on HMGB1-induced inflammatory responses in vitro and in vivo. J Cell Physiol (2013) 0.88
Development and validation of osteoporosis risk-assessment model for Korean postmenopausal women. J Bone Miner Metab (2013) 0.87
Investigation of oncogenic cooperation in simple liver-specific transgenic mouse models using noninvasive in vivo imaging. PLoS One (2013) 0.87
Concurrent chemoradiotherapy followed by adjuvant chemotherapy in uterine cervical cancer patients with high-risk factors. Gynecol Oncol (2006) 0.87
Feasibility of sorafenib combined with local radiotherapy in advanced hepatocellular carcinoma. Yonsei Med J (2013) 0.87
Age and gender differences in medical care utilization prior to suicide. J Affect Disord (2012) 0.86
Spousal concordance of metabolic syndrome in 3141 Korean couples: a nationwide survey. Ann Epidemiol (2005) 0.86
Helical tomotherapy for spine oligometastases from gastrointestinal malignancies. Radiat Oncol J (2011) 0.86
Effective local control of malignant melanoma by intratumoural injection of a beta-emitting radionuclide. Eur J Nucl Med Mol Imaging (2002) 0.86
Impact of spontaneous hepatocellular carcinoma rupture on recurrence pattern and long-term surgical outcomes after partial hepatectomy. World J Surg (2014) 0.86
Therapeutic benefit of radiotherapy in huge (≥10 cm) unresectable hepatocellular carcinoma. Liver Int (2014) 0.86
Glutathione S-transferase M1 status and breast cancer risk: a meta-analysis. Yonsei Med J (2004) 0.86
Clinical predictors associated with proton pump inhibitor-induced hypomagnesemia. Am J Ther (2015) 0.86
Replacement of microglial cells using Clodronate liposome and bone marrow transplantation in the central nervous system of SOD1(G93A) transgenic mice as an in vivo model of amyotrophic lateral sclerosis. Biochem Biophys Res Commun (2012) 0.85
Differential cyclooxygenase-2 expression in squamous cell carcinoma and adenocarcinoma of the uterine cervix. Int J Radiat Oncol Biol Phys (2004) 0.85